NFE2L2 and hematopoietic and lymphoid cell neoplasm: Other researchers took advantage of global repressors of protein synthesis such as brusatol or halofuginone to facilitate NRF2 degradation and prevent the refilling of its intracellular content at the post-transcriptional level in solid and hematologic tumors.